The National AIDS Commission (NAC) has raised serious concern over a steady increase in HIV cases across Liberia, revealing that the number of people living with the virus has climbed from 34,000 in ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal ...

The United States, whose deep cuts to foreign aid this year under President Trump have severely impacted Africa’s health ...

Administration officials say South Africa has “significant means” to fund a promising new drug, lenacapavir, on its own.

Merck reports positive results from phase 3 trial of once-daily, oral, two-drug, single-tablet regimen of Doravirine/Islatravir in treatment-naïve adults with HIV-1 infection ...

Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...

The safety profile of the regimen was also found to be comparable to Biktarvy. ・Merck now intends to present findings from ...

Eswatini on Tuesday became the first African country to receive lenacapavir, the first twice-yearly HIV prevention injection hailed by global health officials as a game-changer in the fight against a ...

Today, Seema Sahay is Head of Division of Social Behavioural Research at the Indian Council of Medical Research, National Institute of Translational Virology & AIDS Research (NARI), Pune, India.

Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...